[시장보고서]안티센스 및 RNAi 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 기술별, 용도별, 투여 경로별, 지역별, 경쟁별 세분화(2020-2030년)

안티센스 및 RNAi 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 기술별, 용도별, 투여 경로별, 지역별, 경쟁별 세분화(2020-2030년)

Antisense And RNAi Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Application, By Route of Administration, By Region and Competition, 2020-2030F

상품코드 : 1886311

리서치사 : TechSci Research

발행일 : 2025년 12월

페이지 정보 : 영문 182 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,601,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 8,068,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,736,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 안티센스 및 RNAi 치료제 시장은 2024년에 52억 달러로 평가되며, 2030년까지 149억 1,000만 달러에 달할 전망이며, CAGR은 19.19%로 예측됩니다. 안티센스 및 RNAi 치료제는 안티센스 올리고뉴클레오티드에 의한 단백질 생산 억제 또는 RNA 간섭에 의한 메신저 RNA의 분해를 통해 유전자 발현을 정밀하게 조절하는 분자 의약품의 일종으로, 다양한 질환에 대한 표적 치료제를 제공합니다. 시장 확대는 근본적으로 전 세계에서 유전성 질환과 만성질환의 발생률이 증가하고 있으며, 고도로 특이적인 치료법을 설계할 수 있는 복잡한 분자 질환 메커니즘에 대한 이해가 급속도로 발전하고 있기 때문입니다. 연구개발에 대한 투자 확대는 치료 옵션이 제한적인 질환에 대한 치료 대상 영역을 확대함으로써 이러한 성장을 더욱 가속화하고 있습니다.

시장 개요
예측 기간	2026-2030
시장 규모 : 2024년	52억 달러
시장 규모 : 2030년	149억 1,000만 달러
CAGR : 2025-2030년	19.19%
가장 빠르게 성장하는 부문	RNA 간섭
최대 시장	북미

주요 시장 성장 촉진요인

세계 안티센스 및 RNAi 치료제 시장은 유전질환 및 만성질환 증가로 인한 부담 증가에 크게 영향을 받고 있으며, 혁신적인 치료법에 대한 심각한 미충족 수요를 야기하고 있습니다. 이러한 치료법은 유전자 발현을 정밀하게 조절하여 기존 치료법이 효과가 없는 많은 질병의 근본 원인을 해결합니다.

주요 시장 과제

핵산 기반 분자를 특정 세포 및 조직에 효율적이고 정확하게 표적화하여 생체 내(in vivo)로 전달하기 위한 지속적인 복잡성은 세계 안티센스 및 RNAi 치료제 시장의 성장을 직접적으로 저해하고 있습니다. 이 문제는 이러한 분자의 고유한 특성, 예를 들어 크기, 음전하, 효소 분해에 취약한 특성 등으로 인해 생물학적 장벽을 넘어 충분한 농도로 세포내 표적에 도달할 수 있는 능력을 저해하고 있습니다.

주요 시장 동향

안티센스 및 RNAi 치료제는 희귀질환을 넘어 보다 광범위한 치료 영역으로 확대되고 있습니다. 이러한 전략적 다각화에는 심혈관 질환, 대사성 질환, 신경계 질환 등 보다 일반적인 만성질환에 대한 타겟팅이 포함되며, 이는 더 많은 환자 집단에 대한 기술의 적용 가능성에 대한 신뢰가 높아졌음을 보여줍니다.

시장 규모·예측
- 금액별
시장 점유율·예측
- 기술별(RNA 간섭, 안티센스 RNA)
- 투여 경로별(정맥내 주사, 척수강내 주사, 피하 주사, 기타)
- 용도별(안과 영역, 심장대사·신장 질환, 암, 호흡기질환, 피부 질환, 신경변성질환, 유전성 질환, 감염증)
- 지역별
- 기업별(2024)
시장 맵

제6장 북미의 안티센스 및 RNAi 치료제 시장 전망

시장 규모·예측
시장 점유율·예측
북미 : 국가별 분석
- 미국
- 캐나다
- 멕시코

제7장 유럽의 안티센스 및 RNAi 치료제 시장 전망

시장 규모·예측
시장 점유율·예측
유럽 : 국가별 분석
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인

제8장 아시아태평양의 안티센스 및 RNAi 치료제 시장 전망

시장 규모·예측
시장 점유율·예측
아시아태평양 : 국가별 분석
- 중국
- 인도
- 일본
- 한국
- 호주

제9장 중동 및 아프리카의 안티센스 및 RNAi 치료제 시장 전망

시장 규모·예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
- 사우디아라비아
- 아랍에미리트
- 남아프리카공화국

제10장 남미의 안티센스 및 RNAi 치료제 시장 전망

시장 규모·예측
시장 점유율·예측
남미 : 국가별 분석
- 브라질
- 콜롬비아
- 아르헨티나

제11장 시장 역학

촉진요인
과제

제12장 시장 동향과 발전

합병·인수
제품 출시
최근 동향

제13장 세계의 안티센스 및 RNAi 치료제 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

업계내 경쟁
신규 참여의 가능성
공급업체의 힘
고객의 힘
대체품의 위협

제15장 경쟁 구도

Olix Pharmaceuticals, Inc.
GSK plc
Sanofi Aventis S.A.
Alnylam Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Benitec Biopharma Inc
Silence Therapeutics Inc.
Arbutus Biopharma Inc.
Sarepta Therapeutics Inc.
Percheron Therapeutics Limited.

제16장 전략적 제안

제17장 조사회사 소개·면책사항

KSA

영문 목차

영문목차

The Global Antisense And RNAi Therapeutics Market, valued at USD 5.20 Billion in 2024, is projected to experience a CAGR of 19.19% to reach USD 14.91 Billion by 2030. Antisense and RNAi therapeutics represent a molecular medicine class that precisely modulates gene expression by either inhibiting protein production via antisense oligonucleotides or degrading messenger RNA through RNA interference, offering targeted interventions for various diseases. The market's expansion is fundamentally driven by the rising global incidence of genetic and chronic disorders, alongside a burgeoning understanding of intricate molecular disease mechanisms enabling highly specific therapeutic design. Growing investments in research and development further propel this growth by expanding the addressable therapeutic landscape for conditions with limited treatment options.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 5.20 Billion
Market Size 2030	USD 14.91 Billion
CAGR 2025-2030	19.19%
Fastest Growing Segment	RNA Interference
Largest Market	North America

Key Market Drivers

The global Antisense and RNAi Therapeutics Market is significantly influenced by the increasing burden of genetic and chronic diseases, which establishes a profound unmet medical need for innovative treatments. These therapies offer precise modulation of gene expression, addressing the root causes of many disorders where conventional treatments fall short. The substantial patient population suffering from these conditions drives consistent demand for novel therapeutic avenues.

Key Market Challenges

The persistent complexity in achieving efficient and precisely targeted *in vivo* delivery of nucleic acid-based molecules to specific cells and tissues directly impedes the growth of the Global Antisense and RNAi Therapeutics Market. This challenge arises from the inherent properties of these molecules, such as their size, negative charge, and susceptibility to enzymatic degradation, which hinder their ability to cross biological barriers and reach their intracellular targets in sufficient concentrations. Consequently, the development of novel therapies is prolonged due to the extensive research required for suitable delivery vehicles, increasing overall development costs and time to market.

Key Market Trends

Antisense and RNAi therapeutics are increasingly expanding into broader therapeutic areas beyond rare diseases. This strategic diversification involves targeting more prevalent chronic conditions such as cardiovascular, metabolic, and neurological disorders, indicating a growing confidence in the technology's applicability to larger patient populations.

Key Market Players

Olix Pharmaceuticals, Inc.
GSK plc
Sanofi Aventis S.A.
Alnylam Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Benitec Biopharma Inc
Silence Therapeutics Inc.
Arbutus Biopharma Inc.
Sarepta Therapeutics Inc.
Percheron Therapeutics Limited.

Report Scope:

In this report, the Global Antisense And RNAi Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antisense And RNAi Therapeutics Market, By Technology:

RNA Interference
Antisense RNA

Antisense And RNAi Therapeutics Market, By Route of Administration:

Intravenous Injections
Intrathecal Injections
Subcutaneous Injections
Other

Antisense And RNAi Therapeutics Market, By Application:

Ocular
Cardiometabolic & Renal Disorders
Cancer
Respiratory Disorders
Skin Diseases
Neurodegenerative Disorders
Genetic Disorders
Infectious Diseases

Antisense And RNAi Therapeutics Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Antisense And RNAi Therapeutics Market.

Available Customizations:

Global Antisense And RNAi Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antisense And RNAi Therapeutics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Technology (RNA Interference, Antisense RNA)
- 5.2.2. By Route of Administration (Intravenous Injections, Intrathecal Injections, Subcutaneous Injections, Other)
- 5.2.3. By Application (Ocular, Cardiometabolic & Renal Disorders, Cancer, Respiratory Disorders, Skin Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map

6. North America Antisense And RNAi Therapeutics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Technology
- 6.2.2. By Route of Administration
- 6.2.3. By Application
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Antisense And RNAi Therapeutics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Technology
    - 6.3.1.2.2. By Route of Administration
    - 6.3.1.2.3. By Application
- 6.3.2. Canada Antisense And RNAi Therapeutics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Technology
    - 6.3.2.2.2. By Route of Administration
    - 6.3.2.2.3. By Application
- 6.3.3. Mexico Antisense And RNAi Therapeutics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Technology
    - 6.3.3.2.2. By Route of Administration
    - 6.3.3.2.3. By Application

7. Europe Antisense And RNAi Therapeutics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Technology
- 7.2.2. By Route of Administration
- 7.2.3. By Application
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Antisense And RNAi Therapeutics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Technology
    - 7.3.1.2.2. By Route of Administration
    - 7.3.1.2.3. By Application
- 7.3.2. France Antisense And RNAi Therapeutics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Technology
    - 7.3.2.2.2. By Route of Administration
    - 7.3.2.2.3. By Application
- 7.3.3. United Kingdom Antisense And RNAi Therapeutics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Technology
    - 7.3.3.2.2. By Route of Administration
    - 7.3.3.2.3. By Application
- 7.3.4. Italy Antisense And RNAi Therapeutics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Technology
    - 7.3.4.2.2. By Route of Administration
    - 7.3.4.2.3. By Application
- 7.3.5. Spain Antisense And RNAi Therapeutics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Technology
    - 7.3.5.2.2. By Route of Administration
    - 7.3.5.2.3. By Application

8. Asia Pacific Antisense And RNAi Therapeutics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Technology
- 8.2.2. By Route of Administration
- 8.2.3. By Application
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Antisense And RNAi Therapeutics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Technology
    - 8.3.1.2.2. By Route of Administration
    - 8.3.1.2.3. By Application
- 8.3.2. India Antisense And RNAi Therapeutics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Technology
    - 8.3.2.2.2. By Route of Administration
    - 8.3.2.2.3. By Application
- 8.3.3. Japan Antisense And RNAi Therapeutics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Technology
    - 8.3.3.2.2. By Route of Administration
    - 8.3.3.2.3. By Application
- 8.3.4. South Korea Antisense And RNAi Therapeutics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Technology
    - 8.3.4.2.2. By Route of Administration
    - 8.3.4.2.3. By Application
- 8.3.5. Australia Antisense And RNAi Therapeutics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Technology
    - 8.3.5.2.2. By Route of Administration
    - 8.3.5.2.3. By Application

9. Middle East & Africa Antisense And RNAi Therapeutics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Technology
- 9.2.2. By Route of Administration
- 9.2.3. By Application
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Antisense And RNAi Therapeutics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Technology
    - 9.3.1.2.2. By Route of Administration
    - 9.3.1.2.3. By Application
- 9.3.2. UAE Antisense And RNAi Therapeutics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Technology
    - 9.3.2.2.2. By Route of Administration
    - 9.3.2.2.3. By Application
- 9.3.3. South Africa Antisense And RNAi Therapeutics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Technology
    - 9.3.3.2.2. By Route of Administration
    - 9.3.3.2.3. By Application

10. South America Antisense And RNAi Therapeutics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Technology
- 10.2.2. By Route of Administration
- 10.2.3. By Application
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Antisense And RNAi Therapeutics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Technology
    - 10.3.1.2.2. By Route of Administration
    - 10.3.1.2.3. By Application
- 10.3.2. Colombia Antisense And RNAi Therapeutics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Technology
    - 10.3.2.2.2. By Route of Administration
    - 10.3.2.2.3. By Application
- 10.3.3. Argentina Antisense And RNAi Therapeutics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Technology
    - 10.3.3.2.2. By Route of Administration
    - 10.3.3.2.3. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Antisense And RNAi Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Olix Pharmaceuticals, Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. GSK plc
15.3. Sanofi Aventis S.A.
15.4. Alnylam Pharmaceuticals, Inc.
15.5. Ionis Pharmaceuticals, Inc.
15.6. Benitec Biopharma Inc
15.7. Silence Therapeutics Inc.
15.8. Arbutus Biopharma Inc.
15.9. Sarepta Therapeutics Inc.
15.10. Percheron Therapeutics Limited.